News | December 22, 2011

ESC Calls for Studies Exploring Readmissions to Hospital Following PCI

December 22 2011 — A recent United States study on the importance of measuring rates of rehospitalization following percutaneous coronary intervention (PCI) has drawn the attention of the European Society of Cardiology (ESC). The research, published in the JACC Cardiovascular Interventions, represents one of the first studies to explore PCI readmissions. According to ESC, it highlights the need for similar studies to be initiated across Europe to improve patient care.

In the study, Edward Hannan, M.D., and colleagues from the School of Public Health at the University of New York, recorded hospital readmissions for 40,093 patients from New York State. All patients underwent their first PCI procedure between Jan. 1 and Nov. 30, 2007. The retrospective review found a total of 15.6 percent (6,254) of PCI patients were readmitted within 30 days; further analysis revealed that 20.6 percent (1,285) of these readmissions were “staged.” In staging, cardiologists treat the culprit lesion responsible for the initial admission; they then plan for patients to return to the hospital at a future date for treatment of additional lesions.

“Currently we’ve absolutely no idea of the number of patients in Europe who need readmission to hospitals after PCI,” said Prof. Eric Van Belle, an ESC spokesperson from the University of Lille, France. But the U.S. finding that 12.4 percent of PCI patients need to return for unplanned readmissions (not involving staging), he added, was much higher than predicted; to him, this highlighted the need for improvements in care.

 “To allow us to both prevent readmissions by tailoring care to individual patients and produce guidelines around which patients require staging, we need to gain a better handle on data in Europe,” Van Belle said.

Nevertheless, the question remains whether Europe has the infrastructure to identify patients who are likely to be readmitted to multiple hospitals. In the U.S. study, investigators acknowledged that principle diagnoses such as “chronic ischemic heart disease,” “atherosclerosis” and “chest pain” were not specific enough to determine the real reasons for admissions. This left doubts over whether the readmission had been necessitated by a complication of the index procedure or some separate event.

“Achieving a better understanding of the reasons why patients need unplanned admissions would help cardiologists learn how to target interventions to patients at greatest risk of complications,” said ESC spokesperson Prof. Hans Erik Bøtker, from Aarhus University, Skejby, Denmark.

Increased knowledge would also enable hospitals to be adequately reimbursed for the care. “Payments to hospitals could be adjusted to take into account factors such as co-morbidities that are likely to require additional care to prevent repeat hospitalization. The introduction of such systems would remove incentives for hospitals to discharge patients early,” said Bøtker.

The different health care reimbursement systems used in European countries, said Van Belle, influence whether hospitals offer “staged” readmissions. In some countries, hospitals are reimbursed with one fee for a fixed time period regardless of the number of individual procedures or different admissions; while in other countries a separate fee is paid for each admission. The former approach discourages use of staged procedures, while the later serves to encourage them. Both systems, argued Van Belle, can fail to take into account the clinical needs of individual patients.

“For each patient, a risk benefits analysis needs to be undertaken. For most people single procedures (where all the lesions are treated at the same time) carry less overall risks than multiple procedures. However, in certain circumstances when a great number of lesions need to be treated, staged care may be necessary to reduce excessive exposure to radiation,” said Van Belle.

Clearly, he added, evidence-based guidelines are needed to identify the patient groups who would benefit most from staged procedures. “We need to base our decisions on clinical evidence rather than being swayed by financial gain,” said Van Belle.

For more information:

Related Content

Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Scientists Discover New Heart Attack Repair Pathway

A macrophage immune cell, with a dead cell (pink) that has been eaten, and a mitochondrion (green) between the dead cell and the nucleus. The study’s findings indicate that what the macrophage eats is taken up by the mitochondrion, which in turn communicates with the nucleus to activate the macrophage to promote tissue repair. Image courtesy of Northwestern Medicine.

News | Cath Lab | January 30, 2019
Northwestern Medicine scientists have discovered a novel signaling pathway that promotes healing after a heart attack....
Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is a walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Overlay Init